MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib — Stella

Recruiting

Back to Acute Myeloid Leukemia (AML) trials

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(2 sites)

China

the First Affiliated Hosptital of Soochow University, Suzhou, Jiangsu

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai Municipality

Key details

Phase

Large-scale testing

Sponsor

The First Affiliated Hospital of Soochow University

Enrollment target

~594 participants

Started

May 2026

Primary completion

May 2028

Age range

14 Years – 70 Years

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov